Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2009

View Archived Issues

Novel MMP-12 inhibitors synthesized at Wyeth for COPD, asthma

Expanding substrate specificity of botulinum neurotoxins may be useful to treat respiratory diseases

Intercytex temporarily suspends trading of shares on AIM

Cardiome Pharma initiates USD 27.5 million tender offer

Nitec reports phase III results from CAPRA-2 study of Lodotra in RA

Ono reports results from first quarter 2009, ending June 30

Gruenenthal discloses voltage-gated potassium channel activators for pain and other conditions

Merck & Co. describes muscarinic M1 allosteric modulators for Alzheimer's disease therapy

Auspex Pharmaceuticals describes deuterated histamine receptor modulators for allergic rhinitis

Novel biomarkers improve diabetes prediction over traditional risk factors

Aspirin does not prevent vascular events in asymptomatic subjects with low ankle brachial index

Allergan discovers novel antiglaucoma agents

Constrictive remodeling seen with rosiglitazone in diabetic CAD patients

Anti-inflammatory CCR2 antagonists with improved pharmacokinetics identified by GlaxoSmithKline

Depressive symptoms correlate with reduced frontal and temporal brain volumes

Tioga and Ono sign license agreement for asimadoline in Japan, South Korea and Taiwan

FDA committee requests additional clinical trial prior to approval of Vion's Onrigin

FDA recommends randomized clinical trial to support label expansion for Genzyme's Clolar in AML

PTC Therapeutics and Roche sign drug discovery collaboration utilizing GEMS technology

Results from NCI study of PharmaGap's GAP-107-B-8 to be reported in September 2009

FDA approves Meda's nasal antihistamine Astepro for seasonal and perennial allergic rhinitis

Dainippon Sumitomo Pharma to acquire Sepracor through cash tender offer

Bayer Schering Pharma and Algeta sign development and commercialization agreement for Alpharadin

FDA grants fast track designation to Knopp Neurosciences for KNS-760704 in ALS

MethylGene initiates phase II MGCD-265 trial in solid tumors and lung cancer

Acrux to submit NDA to FDA for Axiron for testosterone deficiency in men by end of 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...